Quicksilver Scientific

Due to high demand & labor shortages we are experiencing significant shipping delays. We greatly appreciate your patience. 

Search site wide
Search
0

Unsupported Browser

This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.

NAD+ Gold Methyl Charge Bundle References

NAD Gold+ References quicksilverscientific.com/nadgoldreferences/

  1. Longo VD et al. Interventions to Slow Aging in Humans: Are We Ready? Aging Cell 14 (4): 497-510. View Abstract
  2. Fang EF et al. NAD (+) in aging: molecular mechanisms and translational implications. Trends Mol Med. 2017;23(10):899–916 View Abstract
  3. Wu, L et al. The elusive NMN transporter is found. Nat Metab 2019: 1; 8-9  View Full Paper
  4. Rajman L et al. Therapeutic potential of NAD-Boosting molecules: The in vivo evidence. Cell Metab. 2018 Mar 6;27(3):529-547. View Abstract
  5. Li W et al. NAD+ Content and Its Role in Mitochondria. Mitochondrial Regulation. 2014: 39–48 View Abstract
  6. Lee CF et al. Targeting NAD+ metabolism as interventions for mitochondrial disease. Sci Rep. 2019 Feb 28;9(1):3073. View Abstract
  7. Schultz MB et al. Why NAD+ Declines during Aging: It’s Destroyed. Cell Metab. 2016 June 14; 23(6): 965–966 View Full Paper
  8. Davila, A et al. Nicotinamide adenine dinucleotide is transported into mammalian mitochondria. Elife. 2018 Jun 12;7 View Full Paper
  9. Imai S. The NAD World 2.0: the importance of the inter-tissue communication mediated by NAMPT/NAD+/SIRT1 in mammalian aging and longevity control. NPJ Syst Biol Appl. 2016 Aug 18;2:16018 View Full Paper
  10. Massudi H et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue PLoS One. 2012;7(7):e42357 View Abstract
  11. Zhu XH et al. In vivo NAD assay revels the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc. Natl. Acad. Sci. 2015; 112:2876–2881 View Full Paper
  12. Hershberger KA et al. Role of NAD+ and mitochondrial sirtuins in cardiac and renal diseases. Nat Rev Nephrol. 2017 Apr;13(4):213-225. View Full Paper
  13. Gross CJ et al. Digestion and absorption of NAD by the small intestine of the rat J Nutr. 1983 Feb;113(2):412-20. View Abstract
  14. Poljsak B. NAMPT-Mediated NAD biosynthesis as the internal timing mechanism: in NAD+ World, time Is running in its own way. Rejuvenation Res. 2018 Jun;21(3):210-224 View Abstract
  15. Tsubota, K. The first human clinical study for NMN has started in Japan. NPJ Aging Mech. Dis. 2016, 2, 16021 View Abstract
  16. Strait, JE. Scientists identify new fuel-delivery route for cells. Washington University School of Medicine. Available at: https://medicine.wustl.edu/news/scientists-identify-new-fuel-delivery-route-for-cells/ Accessed: 9-14-2019
  17. Mills KF et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016: 24, 795–806. View Full Paper
  18. Anti-Aging compound in human clinical trial: will boosting NMN slow aging? Available at: https://hecmedia.org/posts/anti-aging-compound-in-human-clinical-trial-will-boosting-nmn-slow-aging-6/ Accessed 9-1-2019
  19. Guan Y et al. Nicotinamide Mononucleotide, an NAD+ precursor, rescues age-associated susceptibility to AKI in a sirtuin 1-dependent manner. J Am Soc Nephrol. 2017 Aug;28(8):2337-2352. View Full Paper
  20. Martin As et al. Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich’s ataxia cardiomyopathy model.JCI Insight. 2017 Jul 20;2(14). View Full Paper
  21. Johnson S et al. NAD + biosynthesis, aging, and disease. F1000Res. 2018 Feb 1;7:132 View Full Paper
  22. Mills KF et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metab. 2016; 24:795–806 View Full Paper
  23. Das A et al. Impairment of an Endothelial NAD+-H2S Signaling Network Is a Reversible Cause of Vascular Aging. Cell. 2018 Mar 22;173(1):74-89.e20 View Abstract
  24. Kathirvel E et al. Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine Am J Physiol Gastrointest Liver Physiol. 2010 Nov;299(5):G1068-77  View Full Paper
  25. Schmeisser K et al. Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide. Nat Chem Biol. 2013;9(11):693–700. View Full Paper
  26. Bonkowski MS et al. Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nat Rev Mol Cell Biol. 2016 November ; 17(11): 679–690 View Full Paper
  27. Kane AE et al. Sirtuins and NAD+ in the development and treatment of metabolic and cardiovascular disease. Circ Res. 2018 Sep 14;123(7):868-885. View Full Paper
  28. Sun WP et al. Comparison of the effects of nicotinic acid and nicotinamide degradation on plasma betaine and choline levels. Clin Nutr, 2017. 36(4): p. 1136-1142 View Abstract
  29. Van der Meel R et al. Extracellular vesicles as drug delivery systems: lessons from the liposome field. J Control Release. 2014 Dec 10;195:72-85 View Abstract
  30. Yoshida M. Extracellular vesicle-contained eNAMPT delays aging and extends lifespan in mice. Cell Metab. 2019 Aug 6;30(2):329-342.e5 View Abstract
  31. Yoshino J et al. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018 Mar 6;27(3):513-528 View Full Paper
  32. Gaddipati R et al. Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. Ann Hepatol. 2010;9(3):266–70. View Abstract
  33. Revollo JR et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007;6(5):363–75 View Full Paper
  34. Caton PW et al. Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated
  35. impairment of mouse islet function. Diabetologia. 2011;54(12):3083–92. View Abstract
  36. De Picciotto NE et al. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell 2016, 15, 522–530. View Full Paper
  37. Yoshino J et al. Nicotinamide mononucleotide, a key NAD (+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14(4):528–36 View Full Paper
  38. Uddin GM et al. Head to Head Comparison of Short-Term Treatment with the NAD(+) Precursor Nicotinamide Mononucleotide (NMN) and 6 Weeks of Exercise in Obese Female Mice. Front. Pharmacol. 2016, 7, 258 View Full Paper
  39. Wei CC et al. Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2/HO-1 signaling pathway. Sci. Rep. 2017, 7, 717 View Full Paper
  40. Wang X et al. Nicotinamide mononucleotide protects against –amyloid oligomer-induced cognitive impairment and neuronal death. Brain Res. 2016, 1643, 1–9. View abstract
  41. Yao Z et al. Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease. Neurosci. Lett. 2017, 647, 133–140. View Abstract
  42. Hou Y et al. NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc. Natl. Acad. Sci. USA 2018, 115, E1876–E1885 View Abstract
  43. Wei CC et al. NAD replenishment with nicotinamide mononucleotide protects blood-brain barrier integrity and attenuates delayed tissue plasminogen activator-induced haemorrhagic transformation after cerebral ischaemia. Br J Pharmacol. 2017 Nov;174(21):3823-3836 View Full Paper
  44. Gomes AP et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 2013; 155, 1624–1638.View Full Paper
  45. Stromsdorfer KL et al. NAMPT-Mediated NAD(+) biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice. Cell Rep. 2016 Aug 16;16(7):1851-60. View Abstract
  46. Camacho-Pereira J et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016; 23:1127–1139 View Full Paper
  47. Lin JB et al. NAMPT-Mediated NAD(+) Biosynthesis Is Essential for Vision In Mice. Cell Rep. 2016; 17:69–85 View Full Paper
  48. Sheedfar F et al. Liver diseases and aging: friends or foes? Aging Cell. 2013 Dec;12(6):950-4 View Abstract
  49. Hamaguchi M. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women.
  50. World J Gastroenterol. 2012 Jan 21;18(3):237-43 View Full Paper
  51. Day CR et al. Betaine chemistry, roles, and potential use in liver disease. Biochim Biophys Acta. 2016 Jun;1860(6):1098-106 View Abstract
  52. Zhao G et al. Betaine in inflammation: mechanistic aspects and applications.  Front Immunol. 2018 May 24;9:1070. View Full Paper
  53. Ueland PM et al. Betaine: a key modulator of one-carbon metabolism and homocysteine status.
  54. Clin Chem Lab Med. 2005;43(10):1069-75. View Abstract
  55. Craig SA. Betaine in human nutrition. Am J Clin Nutr. 2004 Sep;80(3):539-49. View Abstract

Methyl Charge+™ References quicksilverscientific.com/methylchargereferences/

  1. McKee SE et al. Effect of supplementation with methyl-donor nutrients on neurodevelopment and cognition: considerations for future research Nutrition Reviews, 2018 (75): 7:497-511 View Full Paper
  2. Williams AC et al. Nicotinamide, NAD(P)(H), and methyl-group homeostasis evolved and became a determinant of ageing diseases: hypotheses and lessons from Pellagra. Curr Gerontol Geriatr Res. 2012;2012:302875. View Full Paper
  3. Longo VD et al. Interventions to Slow Aging in Humans: Are We Ready? Aging Cell 14 (4): 497-510. View Abstract
  4. Fang EF et al. NAD (+) in aging: molecular mechanisms and translational implications. Trends Mol Med. 2017;23(10):899–916 View Abstract
  5. Hershberger KA et al. Role of NAD+ and mitochondrial sirtuins in cardiac and renal diseases. Nat Rev Nephrol. 2017 Apr;13(4):213-225. View Full Paper
  6. Tasselli L et el. Methylation gets into rhythm with NAD(+)-SIRT1Nat Struct Mol Biol. 2015 Apr;22(4):275-76 View Abstract
  7. Aguilar-Arnal L et al. NAD(+)-SIRT1 control of H3K4 trimethylation through circadian deacetylation of MLL1.Nat Struct Mol Biol. 2015 Apr;22(4):312-8. View Full Paper
  8. Cantó C et al. NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 2015 Jul 7;22(1):31-53. View Full Paper
  9. Kang-Lee YA et al. Metabolic effects of nicotinamide administration in rats. J Nutr. 1983 Feb;113(2):215-21. View Abstract
  10. Aksoy S et al. Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. J. Biol. Chem. 1994 269, 14835–14840.
  11. Li W et al. NAD+ content and its role in mitochondria. Mitochondrial Regulation. 2014: 39–48 View Abstract
  12. Lee CF et al. Targeting NAD+ metabolism as interventions for mitochondrial disease. Sci Rep. 2019 Feb 28;9(1):3073. View Abstract
  13. Pelizzola M. The DNA methylome. FEBS Lett. 2011 Jul 7; 585(13): 1994–2000. View Full Paper
  14. Moore LD et al. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38(1):23–38.View Full Paper
  15. Szyf M. The role of DNA hypermethylation and demethylation in cancer and cancer therapy. Curr Oncol. 2008;15(2):72–75. View Full Paper
  16. Friso S et al. One-carbon metabolism and epigenetics. Mol Aspects Med. 2017 Apr;54:28-36. View Abstract
  17. Shames DS, Minna JD et al. DNA methylation in health, disease, and cancer. Curr Mol Med 7: 85-102View Full Paper
  18. gene in diet-induced nonalcoholic fatty liver disease-associated carcinogenesis. Toxicol Sci. 2019 May 14. pii: kfz110 View Full Paper
  19. Ligthart S et al. DNA methylation signatures of chronic low-grade inflammation are associated with complex diseases. Genome Biol. 2016 Dec 12;17(1):255 View Full Paper
  20. NIH U.S. National Library of Medicine, MTHFR gene. Genetics Home Reference Available at: https://ghr.nlm.nih.gov/gene/MTHFR Accessed 1-4-2020
  21. Castro R et al. 5,10-methylenetetrahydrofolate reductase (MTHFR) 677C→T and 1298A→C mutations are associated with DNA hypomethylation. Journal of Medical Genetics 2004;41:454-458View Full Paper
  22. Hustad S et al. Riboflavin and methylenetetrahydrofolate reductase. Madame Curie Bioscience Database [Internet]. View Full Paper
  23. Pinto JT et al. Riboflavin. Advances in Nutrition 2016 (5):5;973-975 View Full Paper
  24. O’Leary F. Vitamin B12 in health and disease Nutrients. 2010 Mar;2(3):299-316. View Full Paper
  25. James JS, Melnyk S et al. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutr. 2009 Jan; 89(1): 425–430 View Full Paper
  26. Belardo A et al. The concomitant lower concentrations of vitamins B6, B9 and B12 may cause methylation deficiency in autistic children J Nutr Biochem. 2019 Aug;70:38-46. View Abstract
  27. Anderson OS e al. Nutrition and epigenetics: an interplay of dietary methyl donors, one-carbon metabolism and DNA methylation.J Nutr Biochem. 2012 Aug;23(8):853-9. View Full Paper
  28. Spector AA et al. Membrane lipid composition and cellular function. J Lipid Res. 1985 Sep;26(9):1015-35View Full Paper
  29. Chang CY et al. Essential fatty acids and human brain. Acta Neurol Taiwan. 2009 Dec;18(4):231-41View Abstract
  30. Porter CJ. Drug delivery to the lymphatic system. Crit Rev Ther Drug Carrier Syst. 1997;14(4):333-93View Full Paper
  31. Ahn H, Park JH. Liposomal delivery systems for intestinal lymphatic drug transport.Biomater Res. 2016 Nov 23;20:36View Full Paper
  32. Alyautdin R et al. Nanoscale drug delivery systems and the blood brain barrier. Int J Nanomedicine. 2014 Feb 7;9:795-811View Full Paper
0
Your Cart

cyber monday

SALE

25% OFF

USE CODE: CM25

25% OFF Site-Wide

USE CODE: BF25

Exclusions apply: Offer does not include the following products: All Detox Protocols (except Push-Catch), Bio-Age Reversal Protocol, 30-Day Reset, Quinton® and QuintEssential® products, Biocidin® LSF, Clearway Cofactors®, and H2 Elite®. Discount cannot be combined with any other offers, promotions, or coupons.